1,4-二氧代-2,3-二溴甲基喹啉
1,4-二氧代-2,3-二溴甲基喹啉 性质
熔点 | 180-190 °C (decomp) |
---|---|
沸点 | 512.3±60.0 °C(Predicted) |
密度 | 1.95±0.1 g/cm3(Predicted) |
溶解度 | DMF:25mg/mL; DMF:PBS(pH 7.2)(1:1):0.5 mg/ml;二甲基亚砜:20mg/mL |
形态 | 结晶固体 |
酸度系数(pKa) | 1.91±0.30(Predicted) |
颜色 | 白色至黄色 |
1,4-二氧代-2,3-二溴甲基喹啉 用途与合成方法
IC50: 23 µM ( T. gondii enzyme peroxiredoxin II (TgPrxII))
Peroxiredoxins are a widely conserved family of enzymes that function in antioxidant defense and signal transduction. And the changes in PrxII expression are associated with a variety of human diseases, including cancer.Conoidin A binds to the peroxidatic cysteine of TgPrxII, inhibiting its enzymatic activity in vitro. Conoidin A also shown to alkylate or crosslink catalytic cysteines of wild type AcePrx-1 in Ancylostoma ceylanicum and human PrxII and PrxIV with similar efficiency. But it is ineffective to mitochondrial hPrxIII.Conoidin A (5 µM) can inhibit the glucose oxidase-mediated hyperoxidation of mammalian peroxiredoxin I and II.
Conoidin A (intraperitoneal injection; 5 mg/kg; for three successive days before MI/R injury) blocks the effect of Luteolin (HY-N0162) on the ST‐segment elevation. Furthermore, an increase in the infarct size presented of the MI/R group can be reduced by Luteolin. But pre‐treatment with conoidin A abolishs the effect of Luteolin. Pre‐treatment with conoidin A also prevents Luteolin-reduced activities of CK‐MB, AST and LDH in vivo .
Animal Model: | Rat myocardial I/R model |
Dosage: | 5 mg/kg |
Administration: | Intraperitoneal injection; 5 mg/kg; for three successive days before MI/R injury |
Result: | Significantly reversed the antioxidative effect of Luteolin. Impaired the protective effects of luteolin. |
1,4-二氧代-2,3-二溴甲基喹啉 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-11-08 | HY-116090 | 1,4-二氧代-2,3-二溴甲基喹啉 | 18080-67-6 | 25mg | 500 |
2024-11-08 | HY-116090 | 1,4-二氧代-2,3-二溴甲基喹啉 | 18080-67-6 | 10mM * 1mLin DMSO | 550 |